ArticleCancers2025
TILDA-X: Transcriptome-Informed Lung Cancer Disparities via Explainable AI.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLung cancer is a leading cause of cancer-related mortality, with disparities in incidence and outcomes observed across different racial and sex groups. Identifying both patient-specific and cohort-specific disparity biomarkers is critical for developing targeted treatments. The lung cancer dataset is highly imbalanced across races, leading to biased results in disparity information if classification is based on race.
methodThis study developed an explainable artificial intelligence-based framework, TILDA-X, which designs classification models based on disease conditions instead of races to mitigate racial imbalance in the dataset and applies explainable AI to delineate patient-specific disparity information. A lung cancer transcriptome dataset with three disease conditions-lung adenocarcinoma, lung squamous cell carcinoma, and healthy samples-was used to develop classification models. Applying a bottom-up approach from patient-specific disparity information, the cohort-specific disparity information is discovered for different racial and sex groups, African American males, European American males, African American females, and European American females.
resultsClassification based on disease conditions achieved accuracy between 88% and 100% for minority groups (African American males and females), whereas it was only between 0% and 16% for race-based classification, which underscores the significance of the proposed approach. Functional analysis of sub-cohort-specific biomarker genes revealed unique pathways associated with lung cancers in different races and sexes. Among the significant pathways identified, over ~63% overlapped with previously reported lung cancer-related studies, supporting the biological validity of our findings. Overall, combining disease conditions-based classification with explainable AI, this study provides a robust, interpretable framework for characterizing race- and sex-specific disparities in lung cancer, offering a foundation for precision oncology and equitable therapeutic development based on transcriptome profile only.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.